SCHEMBL11028483

SCHEMBL11028483

COc1ccc(Cc2cnc(C(N)=O)c(Nc3ccc(N4CCN(C)CC4)cc3)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.49
▸ ERBB3 P21860 1/20 0.49
▸ FGFR3 P22607 2/20 0.49
▸ VNN1 O95497 1/20 0.49
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SLC2A1 P11166 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ GAA P10253 1/20 0.48
▸ DNMT1 P26358 1/20 0.47
▸ RAD52 P43351 1/20 0.47
▸ JAK2 O60674 2/20 0.45
▸ PTK2 Q05397 1/20 0.45
▸ MAPKAPK2 P49137 1/20 0.45
▸ HTR1A P08908 1/20 0.44
▸ HTR1D P28221 1/20 0.44
▸ HTR1B P28222 1/20 0.44
▸ STAT6 P42226 1/20 0.44
▸ AURKA O14965 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11031933 0.90 MAPKAPK2 (0.51) EGFRERBB3FGFR3VNN1SLC2A1
SCHEMBL11029543 0.90 MAPKAPK2 (0.49) EGFRNPC1RAB9ASLC2A1MAPKAPK2
SCHEMBL11028773 0.89 MAPKAPK2 (0.50) EGFRNPC1RAB9ASLC2A1PTK2
SCHEMBL11025349 0.89 SLC2A1 (0.52) EGFRRAB9ASLC2A1RAD52JAK2
SCHEMBL11025081 0.89 STAT6 (0.55) EGFRNPC1RAB9ASLC2A1KMT2A
SCHEMBL11029564 0.86 TNIK (0.52) EGFRNPC1RAB9ASLC2A1PTK2
SCHEMBL11027886 0.85 SLC2A1 (0.47) EGFRSLC2A1PTK2MAPKAPK2STAT6
SCHEMBL11027435 0.85 STAT6 (0.49) EGFRSLC2A1PTK2MAPKAPK2STAT6
SCHEMBL11027457 0.85 CDK2 (0.50) EGFRERBB3FGFR3NPC1RAB9A
SCHEMBL11030519 0.83 MAPKAPK2 (0.49) EGFRSLC2A1JAK2PTK2MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 EGFR 44/4885ERBB3 10/4885FGFR3 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback